日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer

结缔组织生长因子是肾癌抗血管生成疗法耐药的原因之一

Teisseire, Manon; Karaulic, Arthur; Parola, Julien; Totobesola, Maëva; Borchiellini, Delphine; Pace-Loscos, Tanguy; Schiappa, Renaud; Chamorey, Emmanuel; Durivault, Jérôme; Dufies, Maëva; Ambrosetti, Damien; Luciano, Frédéric; Gao, Juan; Cao, Yihai; Pagès, Gilles; Giuliano, Sandy

De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma.

从头合成丝氨酸是一种代谢弱点,可以利用这种弱点来克服晚期肾细胞癌的舒尼替尼耐药性

Teisseire Manon, Sahu Umakant, Parola Julien, Tsai Meng-Chen, Vial Valérie, Durivault Jérôme, Grépin Renaud, Cormerais Yann, Molina Clément, Gouraud Arthur, Pagès Gilles, Ben-Sahra Issam, Giuliano Sandy

New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments

新型CXCR1/CXCR2抑制剂为治疗对现有疗法敏感或耐药的肾癌或头颈癌提供了一种有效的治疗方法。

Dufies, Maeva; Grytsai, Oleksandr; Ronco, Cyril; Camara, Oumar; Ambrosetti, Damien; Hagege, Anaïs; Parola, Julien; Mateo, Lou; Ayrault, Marion; Giuliano, Sandy; Grépin, Renaud; Lagarde, Nathalie; Montes, Matthieu; Auberger, Patrick; Demange, Luc; Benhida, Rachid; Pagès, Gilles

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma

可溶性CD146是透明细胞肾细胞癌恶化和舒尼替尼疗效的预测标志物。

Dufies, Maeva; Nollet, Marie; Ambrosetti, Damien; Traboulsi, Wael; Viotti, Julien; Borchiellini, Delphine; Grépin, Renaud; Parola, Julien; Giuliano, Sandy; Helley-Russick, Dominique; Bensalah, Karim; Ravaud, Alain; Bernhard, Jean-Christophe; Schiappa, Renaud; Bardin, Nathalie; Dignat-George, Françoise; Rioux-Leclercq, Nathalie; Oudard, Stephane; Négrier, Sylvie; Ferrero, Jean-Marc; Chamorey, Emmanuel; Blot-Chabaud, Marcel; Pagès, Gilles